Tradestie Institutional Equity Comparison Engine

MNOV vs ACHV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin while ACHV counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
MNOV 8.5x vs ACHV 35.3x Fwd P/E
Growth & Margin Winner MNOV
Op Margin -1232.2% vs 0.0% ยท YoY +12.4% vs +0.0%
Momentum & Technical Winner ACHV
1Y -8.4% vs +43.0% ยท 52W Pos 3% vs 69%
Options & Structure Winner ACHV
UNCLASSIFIED (50th %ile IV) vs BREAKOUT (23rd %ile IV)
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MNOV -8.39% ACHV +43.04% Spread: +54.14 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MNOV TTM Op. Margin: -1232.2% ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNOV vs ACHV. Trailing 12-month operating profitability (MNOV -1232.2% vs ACHV 0.0%) and valuation multiples (MNOV 8.5x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MNOV (5) vs ACHV (4)
Institutional Metric MNOV ACHV Criterion Row Winner
Market Capitalization Scale $65.1M $692.8M Larger Scale ACHV
Trailing P/E Ratio Valuation 8.5x 35.3x Lower Multiple MNOV
Forward P/E Ratio Valuation 8.5x 35.3x Lower Multiple MNOV
Revenue Growth (YoY) Growth +12.4% +0.0% Higher Growth MNOV
Operating Margin (TTM) Profitability -1232.2% 0.0% Higher Margin ACHV
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -24.8% -845.0% Higher ROE MNOV
52-Week Range Position Momentum 3% ($1โ€“$4) 69% ($3โ€“$9) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 38% Vol 1.73ฮฒ ยท 62% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MNOV vs ACHV Buy Guide
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MNOV nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.